trial · primary record
Ibrutinib
Chronic Lymphocytic Leukemia
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 539 |
| Primary completion | 2029-12-31 |
| Primary endpoint | Number of participants affected by an adverse event |
| Registry ID | NCT01804686 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:15.278Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01804686
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.